PL3231444T3 - Nowe leczenie - Google Patents

Nowe leczenie

Info

Publication number
PL3231444T3
PL3231444T3 PL17174446T PL17174446T PL3231444T3 PL 3231444 T3 PL3231444 T3 PL 3231444T3 PL 17174446 T PL17174446 T PL 17174446T PL 17174446 T PL17174446 T PL 17174446T PL 3231444 T3 PL3231444 T3 PL 3231444T3
Authority
PL
Poland
Prior art keywords
new treatment
treatment
new
Prior art date
Application number
PL17174446T
Other languages
English (en)
Inventor
Katharine ABBOTT-BANNER
John Hanrahan
David Thomas
Original Assignee
Verona Pharma Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1408384.4A external-priority patent/GB201408384D0/en
Priority claimed from GBGB1417719.0A external-priority patent/GB201417719D0/en
Application filed by Verona Pharma Plc filed Critical Verona Pharma Plc
Publication of PL3231444T3 publication Critical patent/PL3231444T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/05—Immunological preparations stimulating the reticulo-endothelial system, e.g. against cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL17174446T 2014-05-12 2015-05-11 Nowe leczenie PL3231444T3 (pl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB1408384.4A GB201408384D0 (en) 2014-05-12 2014-05-12 New treatment
GBGB1417719.0A GB201417719D0 (en) 2014-10-07 2014-10-07 New treatment
PCT/GB2015/051377 WO2015173551A1 (en) 2014-05-12 2015-05-11 New treatment
EP15724354.4A EP3142701B1 (en) 2014-05-12 2015-05-11 New treatment
EP17174446.9A EP3231444B1 (en) 2014-05-12 2015-05-11 New treatment

Publications (1)

Publication Number Publication Date
PL3231444T3 true PL3231444T3 (pl) 2020-05-18

Family

ID=53264683

Family Applications (2)

Application Number Title Priority Date Filing Date
PL17174446T PL3231444T3 (pl) 2014-05-12 2015-05-11 Nowe leczenie
PL15724354T PL3142701T3 (pl) 2014-05-12 2015-05-11 Nowe leczenie

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL15724354T PL3142701T3 (pl) 2014-05-12 2015-05-11 Nowe leczenie

Country Status (16)

Country Link
US (2) US10864213B2 (pl)
EP (2) EP3231444B1 (pl)
AU (1) AU2015261239B2 (pl)
CA (1) CA2948620C (pl)
CY (2) CY1120550T1 (pl)
DK (2) DK3231444T3 (pl)
ES (2) ES2682105T3 (pl)
HU (1) HUE048020T2 (pl)
IL (1) IL248856B (pl)
MX (1) MX377387B (pl)
PL (2) PL3231444T3 (pl)
PT (2) PT3231444T (pl)
RU (1) RU2688191C2 (pl)
SI (2) SI3231444T1 (pl)
WO (1) WO2015173551A1 (pl)
ZA (1) ZA201607705B (pl)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007079139A2 (en) 2005-12-28 2007-07-12 Vertex Pharmaceuticals, Inc. Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
ES2608474T3 (es) 2010-04-22 2017-04-11 Vertex Pharmaceuticals Incorporated Proceso de producción de compuestos indol cycloalkylcarboxamido
ES2885181T3 (es) 2014-04-15 2021-12-13 Vertex Pharma Composiciones farmacéuticas para el tratamiento de enfermedades mediadas por el regulador de la conductancia transmembrana de fibrosis quística
PL3231444T3 (pl) 2014-05-12 2020-05-18 Verona Pharma Plc Nowe leczenie
MY196072A (en) 2014-09-15 2023-03-13 Verona Pharma Plc Liquid Inhalation Formulation Comprising RPL554
GB201502260D0 (en) 2015-02-11 2015-04-01 Verona Pharma Plc Salt of Pyrimido[6,1-A]Isoquinolin-4-one compound
GB201613054D0 (en) 2016-07-28 2016-09-14 Verona Pharma Plc New compound and process
IT201700085714A1 (it) * 2017-07-26 2019-01-26 Luigi Maiuri Approccio terapeutico per il trattamento e/o prevenzione di condizioni di sensibilità al glutine.
GB2578093B (en) * 2018-10-09 2020-11-18 Verona Pharma Plc Liquid pharmaceutical composition comprising RPL554 and HFA-134A
GB201911517D0 (en) * 2019-08-12 2019-09-25 Verona Pharma Plc Pharmaceutical composition
WO2021133782A1 (en) * 2019-12-26 2021-07-01 National Jewish Health Methods of treating cystic fibrosis transmembrane conductance regulator (cftr) dysfunction
GB202202297D0 (en) 2022-02-21 2022-04-06 Verona Pharma Plc Formulation production process
EP4378942A1 (en) 2022-12-02 2024-06-05 Sandoz AG Crystal form of a pde3/4 inhibitor
AU2024309346C1 (en) 2023-06-26 2026-03-12 Verona Pharma Plc Particulate composition comprising ensifentrine
WO2025093848A1 (en) 2023-11-01 2025-05-08 Verona Pharma Plc Ensifentrine for treating bronchiectasis

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE455946B (sv) 1986-10-20 1988-08-22 Trion Forskning & Utveckling Nya pertussistoxin-polypeptider och antigener samt testsatser, vacciner och intradermala hudtestkompositioner
US5874063A (en) 1991-04-11 1999-02-23 Astra Aktiebolag Pharmaceutical formulation
AU2178392A (en) 1991-06-12 1993-01-12 Minnesota Mining And Manufacturing Company Albuterol sulfate suspension aerosol formulations
JP3908269B2 (ja) 1991-12-18 2007-04-25 スリーエム カンパニー 懸濁エアゾール製剤
US5983956A (en) 1994-10-03 1999-11-16 Astra Aktiebolag Formulation for inhalation
SE9501384D0 (sv) 1995-04-13 1995-04-13 Astra Ab Process for the preparation of respirable particles
US6040344A (en) 1996-11-11 2000-03-21 Sepracor Inc. Formoterol process
ATE228823T1 (de) 1998-04-18 2002-12-15 Glaxo Group Ltd Pharmazeutische aerosolformulierung
GB9808802D0 (en) 1998-04-24 1998-06-24 Glaxo Group Ltd Pharmaceutical formulations
SE9804000D0 (sv) 1998-11-23 1998-11-23 Astra Ab New composition of matter
DE60005493T2 (de) 1999-03-31 2004-07-01 Vernalis Ltd., Wokingham Pyrimido[6,1-a]isochinolinonderivate
DK1169019T3 (da) 1999-04-14 2003-06-02 Glaxo Group Ltd Farmaceutisk aerosolformulering
LT2502911T (lt) 2004-06-24 2017-09-11 Vertex Pharmaceuticals Incorporated Atp surišančios kasetės transporterių moduliatoriai
EP2100599A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2365972B1 (en) 2008-11-06 2014-12-17 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
AU2010294598B2 (en) 2009-09-11 2016-09-01 Chiesi Farmaceutici S.P.A. Pregnane derivatives condensed in the 16, 17 position with an n-substituted isoxazolidine ring as anti-inflammatory agents
PH12013500261A1 (en) 2010-08-09 2013-03-04 Verona Pharma Plc Crystalline form of pyrimidio[6,1-a]isoquinolin-4-one compound
WO2012069275A1 (en) 2010-11-26 2012-05-31 Chiesi Farmaceutici S.P.A. Glycine derivatives and their use as muscarinic receptor antagonists
WO2012107364A1 (en) 2011-02-07 2012-08-16 Scipharm Sàrl Novel composition for the treatment of cystic fibrosis
JP2014525927A (ja) * 2011-08-18 2014-10-02 シャイアー アーゲー 治療法に使用される５−ｈｔ４受容体アゴニスト及びｐｄｅ４阻害剤の組合せ
EP2819670A1 (en) * 2012-02-27 2015-01-07 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administration thereof
CN105229547A (zh) 2013-03-14 2016-01-06 林肯环球股份有限公司 导出或者使用针对外部系统的焊接定序器数据的系统和方法
EP2968312B1 (en) 2013-03-15 2018-01-31 Verona Pharma PLC Drug combination
PL3231444T3 (pl) 2014-05-12 2020-05-18 Verona Pharma Plc Nowe leczenie
MY196072A (en) 2014-09-15 2023-03-13 Verona Pharma Plc Liquid Inhalation Formulation Comprising RPL554
GB201502260D0 (en) 2015-02-11 2015-04-01 Verona Pharma Plc Salt of Pyrimido[6,1-A]Isoquinolin-4-one compound
GB201613054D0 (en) 2016-07-28 2016-09-14 Verona Pharma Plc New compound and process
GB2578093B (en) 2018-10-09 2020-11-18 Verona Pharma Plc Liquid pharmaceutical composition comprising RPL554 and HFA-134A
GB202002786D0 (en) 2020-02-27 2020-04-15 Verona Pharma Plc Liquid pharmaceutical composition

Also Published As

Publication number Publication date
RU2016148447A3 (pl) 2018-12-27
US10864213B2 (en) 2020-12-15
EP3142701A1 (en) 2017-03-22
SI3142701T1 (en) 2018-08-31
EP3231444B1 (en) 2019-12-18
WO2015173551A1 (en) 2015-11-19
PT3231444T (pt) 2020-03-05
ES2773142T3 (es) 2020-07-09
CA2948620A1 (en) 2015-11-19
MX2016014756A (es) 2017-03-23
AU2015261239B2 (en) 2020-02-27
HUE048020T2 (hu) 2020-05-28
PL3142701T3 (pl) 2018-11-30
DK3142701T3 (en) 2018-08-13
CA2948620C (en) 2023-01-24
RU2016148447A (ru) 2018-06-19
US20210106585A1 (en) 2021-04-15
EP3231444A1 (en) 2017-10-18
IL248856B (en) 2020-07-30
MX377387B (es) 2025-03-10
AU2015261239A1 (en) 2016-12-01
DK3231444T3 (da) 2020-03-16
ZA201607705B (en) 2020-05-27
PT3142701T (pt) 2018-10-18
CY1120550T1 (el) 2019-07-10
US11759467B2 (en) 2023-09-19
ES2682105T3 (es) 2018-09-18
CY1122748T1 (el) 2021-03-12
SI3231444T1 (sl) 2020-04-30
EP3142701B1 (en) 2018-06-27
US20170112839A1 (en) 2017-04-27
IL248856A0 (en) 2017-01-31
RU2688191C2 (ru) 2019-05-21

Similar Documents

Publication Publication Date Title
SI3132034T1 (sl) Zdravstveni pripomočki
IL248856B (en) New treatment
GB201502137D0 (en) Treatment
GB201522243D0 (en) Treatment
SG11201601030VA (en) Massager
GB201401430D0 (en) Treatment process
GB201410216D0 (en) Therapeutic
PT3099317T (pt) Tripsina de bacalhau para utilização no tratamento de infeções microbianas num indivíduo com imunodeficiência
GB201519450D0 (en) Novel treatment
GB201406989D0 (en) Novel treatments
GB201412011D0 (en) Treatments
GB201510637D0 (en) Therapeutic
GB201508841D0 (en) Treatment
GB201411027D0 (en) Treatment
GB201503008D0 (en) Treatment
GB201412411D0 (en) Treatment
GB201414542D0 (en) Novel therapy
GB201410334D0 (en) Therapeutic
GB201417719D0 (en) New treatment
GB201408384D0 (en) New treatment
GB201413317D0 (en) Atheroscierosis treatment
GB201412410D0 (en) Treatment
GB201400235D0 (en) Treatment
GB201400238D0 (en) Treatment
GB201400240D0 (en) Treatment